<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Justin Floyd, DO
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James P Morgan, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reed E Drews, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cancer patients receiving chemotherapy have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of heart disease.
        </p>
        <p>
         Among the serious complications that have been reported are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arrhythmias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myocardial necrosis causing a dilated cardiomyopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasospasm or vasoocclusion resulting in angina or myocardial infarction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericardial disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arterial occlusive events
        </p>
        <p>
        </p>
        <p>
         A wide range of chemotherapy agents have been associated with cardiotoxicity, for which the anthracyclines and related compounds (which may have been administered in childhood) are the most frequently implicated agents [
         <a href="#rid1">
          1,2
         </a>
         ]. However, many other agents, including conventional cytotoxic and molecularly targeted agents, have the potential to cause cardiotoxicity.
        </p>
        <p>
         The cardiotoxicity of chemotherapy agents other than fluoropyrimidines, anthracyclines, and HER2-targeted therapies will be reviewed here. Most of these data are derived from patients who received these agents as adults rather than children.
        </p>
        <p>
         The cardiotoxicity of anthracyclines, HER2-targeted therapies, fluoropyrimidines (
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         ), molecularly targeted agents that target angiogenesis, and checkpoint inhibitor immunotherapy agents are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/774.html" rel="external">
          "Cardiotoxicity of trastuzumab and other HER2-targeted agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89348.html" rel="external">
          "Fluoropyrimidine-associated cardiotoxicity: Incidence, clinical manifestations, mechanisms, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Left ventricular dysfunction and myocardial ischemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Cardiovascular toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANTIMETABOLITES
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Fludarabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          Fludarabine
         </a>
         , a purine antagonist used in hematologic malignancies, has been reported to cause hypotension and chest pain [
         <a href="#rid3">
          3
         </a>
         ]. In addition, the combination of fludarabine and
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         has been associated with severe cardiac toxicity in at least seven cases when used as the conditioning agent for bone marrow transplantation [
         <a href="#rid4">
          4
         </a>
         ]. The use of either agent alone in high doses has only rarely been associated with cardiac toxicity.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Pentostatin and cladribine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          Pentostatin
         </a>
         (2'-deoxycoformycin) and
         <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">
          cladribine
         </a>
         (2-chlorodeoxyadenosine) are additional purine antagonists used in hematologic malignancies. Both have rarely been reported to cause ischemia and heart failure [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Methotrexate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although no definite cardiac toxicity has been associated with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , there are rare reports of syncope, myocardial infarction, and supraventricular and ventricular arrhythmias associated with its use [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Cytarabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple cases of pericarditis have been attributed to
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         , and this can progress to pericardial effusion and cardiac tamponade [
         <a href="#rid10">
          10-12
         </a>
         ]. Corticosteroid therapy may be beneficial in the treatment of this complication.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          MICROTUBULE-TARGETING DRUGS
         </span>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Vinca alkaloids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension, myocardial ischemia and infarction, and other vaso-occlusive complications have been reported with the vinca alkaloids. These complications have been reported most commonly with
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         , but have also been described with
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         [
         <a href="#rid13">
          13-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Taxanes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paclitaxel
         </strong>
         – Bradycardia and heart block are the most frequently described cardiac effects of
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         , although these usually are asymptomatic [
         <a href="#rid21">
          21,22
         </a>
         ]. The overall incidence of cardiac events in the National Cancer Institute database was low, and routine cardiac monitoring is not required for patients without risk factors [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This was illustrated by a phase II series of 140 women with ovarian cancer, in whom transient asymptomatic bradycardia occurred in 29 percent. More serious cardiac toxicity (atrioventricular conduction block, ventricular tachycardia, cardiac ischemia) was seen in 5 percent [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cardiomyopathy is reported when
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         is combined with
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         . Heart failure has developed in up to 20 percent of patients treated with paclitaxel plus doxorubicin [
         <a href="#rid23">
          23,24
         </a>
         ], although an increased incidence of cardiotoxicity was not seen in all studies [
         <a href="#rid25">
          25
         </a>
         ]. The development of heart failure may occur at cumulative doxorubicin doses that are much lower than would be expected with doxorubicin alone [
         <a href="#rid26">
          26-28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">
          "Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Anthracycline-containing regimens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nanoparticle albumin-bound
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         , Abraxane) has the same cardiac toxicity profile as the non-albumin-bound formulation. Asymptomatic electrocardiographic (ECG) changes, including nonspecific changes, sinus bradycardia, and sinus tachycardia, are most common [
         <a href="#rid29">
          29
         </a>
         ]. Rare cases of chest pain, supraventricular tachycardia, and cardiac arrest have been reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Docetaxel
         </strong>
         – Conduction abnormalities, cardiovascular collapse, and angina have been reported in patients treated with
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         [
         <a href="#rid30">
          30-33
         </a>
         ], although there is no convincing evidence that causally links docetaxel to these complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Like
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         appears to potentiate the cardiotoxicity of anthracyclines. This was illustrated by a trial in which 50 women with newly diagnosed stage III breast cancer were treated with docetaxel plus
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]. Heart failure developed in 8 percent, with a mean decrease in ejection fraction of 20 percent. The total doxorubicin dose was &lt;400 mg/m
         <sup>
          2
         </sup>
         in all of these patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32128127">
         <span class="h2">
          Eribulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. In an uncontrolled open-label ECG study in 26 patients, corrected QT (QTc) prolongation was observed on day 8 of treatment, with no QTc prolongation seen on day 1 [
         <a href="#rid35">
          35
         </a>
         ]. The US Food and Drug Administration-approved labeling recommends ECG monitoring in patients who have heart failure or bradyarrhythmias, and for those who are receiving other drugs known to prolong the QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ). The drug should be avoided in those with congenital long QT syndrome.
        </p>
        <p class="headingAnchor" id="H2666169">
         <span class="h2">
          Ixabepilone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8909" href="/z/d/drug information/8909.html" rel="external">
          Ixabepilone
         </a>
         is an epothilone, a class of nontaxane tubulin polymerizing agents. It is approved as monotherapy and in combination with
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         for treatment of metastatic breast cancer.
        </p>
        <p>
         In a trial comparing
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         with or without
         <a class="drug drug_general" data-topicid="8909" href="/z/d/drug information/8909.html" rel="external">
          ixabepilone
         </a>
         , the frequency of adverse cardiac events (myocardial ischemia, ventricular dysfunction) was higher in the combined arm than with capecitabine alone (1.9 versus 0.3 percent), and supraventricular arrhythmias were seen with combined therapy (0.5 percent) but not with capecitabine alone [
         <a href="#rid36">
          36
         </a>
         ]. Given that cardiotoxicity was not reported in a phase II trial of ixabepilone monotherapy conducted in 126 women with advanced breast cancer [
         <a href="#rid37">
          37
         </a>
         ], it is possible that it is the combination of ixabepilone plus capecitabine that is cardiotoxic. However, the approved manufacturer's labeling for ixabepilone suggests caution in patients with a history of cardiac disease and discontinuation of therapy in patients who develop cardiac ischemia or impaired cardiac function during therapy.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          ALKYLATING AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         (Cy) can cause an acute cardiomyopathy that is associated with high-dose protocols, develops early, and is not related to cumulative dose [
         <a href="#rid38">
          38-42
         </a>
         ]. Cardiotoxicity is a limiting factor for treatment with high-dose Cy, but reduced doses have decreased the incidence of acute complications over recent decades [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-dose Cy for conditioning
         </strong>
         – In a series of 811 patients who received Cy total dose &gt;100 mg/kg as conditioning therapy for allogeneic hematopoietic cell transplantation (HCT), 1.5 percent developed fatal heart failure, a median of four days after first administration [
         <a href="#rid44">
          44
         </a>
         ]. The incidence of heart failure was dose-dependent; heart-failure occurred in 8.5, 1.2, and 0 percent of patients who received a total Cy dose of 200, 120, and 100 mg/kg, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a single-institution study of 56 patients who had a left ventricular ejection fraction (LVEF) ≤45 percent prior to HCT, with median follow-up of 29 months, 12.5 percent developed grade ≥2 cardiac complications, but there were no deaths from cardiac complications; the rate of cardiac complications was not higher than historical controls who had pre-transplant LVEF ≥50 percent [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-transplant Cy
         </strong>
         – Post-transplantation Cy (PTCy; eg, 50 mg/kg on days +3 and +4) has emerged as an important agent for prophylaxis of graft-versus-host-disease (GVHD) in patients undergoing haploidentical allogeneic HCT. Use of PTCy for GVHD prophylaxis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease", section on 'Post-transplant cyclophosphamide (PTCy)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study of 585 patients undergoing allogeneic HCT with PTCy, the incidence of post-HCT cardiotoxicity (arrhythmias, heart failure, pericardial effusion, and/or myocardial ischemia) was 6.5 percent (38 patients) [
         <a href="#rid46">
          46
         </a>
         ]. Cardiotoxicity rates were slightly higher in those who received PTCy compared with those who did not (7.4 versus 5.8 percent), and the development of cardiotoxicity was associated with worse one-year overall survival and non-relapse mortality. Risk factors for cardiotoxicity after Cy included age &gt;55 years; history of hypertension, arrhythmias, diabetes; and other cardiac comorbidities. The authors developed a cardiac risk score based on the sum of these risk factors that predicted cardiotoxicity at day 100 (4, 4, 8, 13, and 37 percent for those with 0, 1, 2, 3, or 4 risk factor).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Ifosfamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          Ifosfamide
         </a>
         has been associated with arrhythmias, ST-T wave changes, and heart failure in a dose-related manner [
         <a href="#rid47">
          47,48
         </a>
         ]. These cardiac complications, when symptomatic, are generally reversible with medical management. Controversy exists whether there is increased cardiotoxicity when ifosfamide is used in combination with anthracyclines [
         <a href="#rid48">
          48-52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Cisplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiotoxicity due to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         can be manifested by supraventricular tachycardia, bradycardia, ST-T wave changes, left bundle branch block, acute ischemic events, myocardial infarction, and ischemic cardiomyopathy [
         <a href="#rid53">
          53,54
         </a>
         ]. This toxicity may be related to electrolyte abnormalities secondary to cisplatin-induced nephrotoxicity. (See
         <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">
          "Cisplatin nephrotoxicity"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         has also been associated with vascular toxicities that include Raynaud phenomenon, hypertension, and cerebral ischemic events. The increased risk of late cardiovascular toxicity in young men who have been cured of testicular germ cell tumors using cisplatin-based chemotherapy is of particular concern. The long-term consequences of treatment in this group are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">
          "Posttreatment follow-up for testicular germ cell tumors", section on 'Treatment-related complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">
          "Treatment-related toxicity in testicular germ cell tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Busulfan
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          Busulfan
         </a>
         is used at high doses as part of the preparative regimen for bone marrow transplantation. One case of endocardial fibrosis has been reported that was attributed to busulfan [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H364985655">
         <span class="h2">
          Trabectedin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is a nonclassical alkylating agent that is approved for use in soft tissue sarcomas after progression on an anthracycline. It has been associated with a low rate of cardiac toxicities, including congestive heart failure and rarely, cardiac arrest [
         <a href="#rid56">
          56,57
         </a>
         ]. The median time to development of grade 3 to 4 cardiotoxicity on trabectedin is 5.3 months [
         <a href="#rid58">
          58
         </a>
         ]. A baseline assessment of ejection fraction should be performed using echocardiogram or multigated acquisition (MUGA) prior to initiation of trabectedin and at two- to three-month intervals while treatment is continued. Trabectedin should be held for a decrease in ejection fraction below the lower limit of normal and permanently discontinued for symptomatic cardiomyopathy or for persistent left ventricular dysfunction that does not recover to the lower limit of normal within three weeks.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          ANTITUMOR ANTIBIOTICS
         </span>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Mitomycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          Mitomycin
         </a>
         causes DNA alkylation and cross-linking [
         <a href="#rid59">
          59
         </a>
         ]. Heart failure has been observed in patients treated with mitomycin, with the incidence increasing at cumulative doses &gt;30 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid60">
          60
         </a>
         ]. Cardiotoxicity may be additive when mitomycin is given with anthracyclines [
         <a href="#rid61">
          61-63
         </a>
         ]. Histologically, the damage resembles radiation-induced cardiac injury [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Bleomycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          Bleomycin
         </a>
         has been associated with several different forms of cardiotoxicity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericarditis is an uncommon but potentially serious complication associated with
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         . In a series of 88 patients with lymphoma receiving bleomycin, pericarditis was observed in two cases [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The acute onset of substernal chest pain has also been reported in less than 3 percent of patients treated with
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         [
         <a href="#rid66">
          66
         </a>
         ]. There are no consistent signs or symptoms associated with these events, and long-term cardiac sequelae have not been observed. Treatment is supportive, and discontinuation of the drug is not needed, as further infusions do not usually cause recurrence of the symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coronary artery disease, myocardial ischemia, and myocardial infarction have been observed in young patients during and after treatment with bleomycin-based chemotherapeutic regimens [
         <a href="#rid67">
          67-69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">
          "Posttreatment follow-up for testicular germ cell tumors", section on 'Treatment-related complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">
          "Treatment-related toxicity in testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          MONOCLONAL ANTIBODIES
         </span>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         , a monoclonal antibody against the CD20 antigen on normal and malignant B lymphocytes, is used to treat a variety of malignant and benign hematologic conditions.
        </p>
        <p>
         Arrhythmias and angina have been reported during less than 1 percent of infusions, and acute infusion-related deaths have been seen in less than 0.1 percent. These deaths appear to be related to an infusion-related complex of hypoxia, pulmonary infiltrates, adult respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock [
         <a href="#rid70">
          70-72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'
         </a>
         .)
        </p>
        <p>
         Long-term cardiac toxicity has not been reported with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         administration.
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Alemtuzumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          Alemtuzumab
         </a>
         targets the CD52 antigen that is present on the cell membrane of most T and B lymphocytes. Alemtuzumab is used to treat T-cell prolymphocytic leukemia. (See
         <a class="medical medical_review" href="/z/d/html/13937.html" rel="external">
          "Treatment of T cell prolymphocytic leukemia", section on 'Alemtuzumab'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          Alemtuzumab
         </a>
         therapy of patients with T-cell lymphomas (mycosis fungoides, Sézary syndrome) is associated with a significant risk of heart failure and/or arrhythmias. Among eight patients treated at MD Anderson Cancer Center, heart failure developed in three, atrial fibrillation in one, and ventricular tachycardia in one [
         <a href="#rid73">
          73
         </a>
         ]. Two patients previously had been treated with
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         , but no other causes of cardiac toxicity were identified. The mechanism of this toxicity is not known, and all patients had partial or total resolution of symptoms after discontinuing treatment.
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          TOPOISOMERASE INHIBITORS
         </span>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h2">
          Etoposide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          Etoposide
         </a>
         has been linked to the development of myocardial infarction and vasospastic angina in several case reports [
         <a href="#rid74">
          74-76
         </a>
         ]. Additionally, etoposide is often a part of cisplatin-based regimens that have been associated with acute and delayed cardiac toxicity. (See
         <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">
          "Posttreatment follow-up for testicular germ cell tumors", section on 'Treatment-related complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h1">
          INTERFERON AND INTERLEUKIN-2
         </span>
         <span class="headingEndMark">
          —
         </span>
         The toxicities of biologic response modifiers are generally not due to a direct cytotoxic effect of the drugs, but rather reflect alterations of cellular physiology.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interferon-alfa
         </strong>
         – Interferon-alfa (IFNa) is used as an adjuvant in patients with melanoma and to treat advanced melanoma and renal cell carcinoma. The cardiovascular side effects of IFNa include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myocardial ischemia and infarction, which are generally related to a prior history of coronary artery disease. These may be due to increased fever or associated flu-like symptoms that increase myocardial oxygen requirements [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Atrial and ventricular arrhythmias have been reported in up to a 20 percent of cases [
         <a href="#rid78">
          78-81
         </a>
         ], and two cases of sudden death have been reported [
         <a href="#rid77">
          77
         </a>
         ]. It is unclear whether prior heart disease is linked to an increased risk of arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prolonged administration of IFNa has been associated with cardiomyopathy, manifested by a depressed ejection fraction and heart failure. The cardiomyopathy was reversible upon cessation of IFNa infusion in some but not all cases [
         <a href="#rid82">
          82-85
         </a>
         ]. The pathogenesis of IFNa-induced cardiomyopathy is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interleukin-2
         </strong>
         – Interleukin-2 is primarily used in the treatment of advanced renal cell cancer. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Interleukin 2 and other interleukins'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Virtually all patients receiving high-dose interleukin-2 (IL-2) develop a capillary leak syndrome associated with increased vascular permeability and hypotension. This results in cardiovascular symptoms similar to those of septic shock, with an increased heart rate and cardiac output and a decrease in systemic peripheral resistance. These symptoms are partially responsive to fluid replacement therapy, but patients often require vasopressors as well. These symptoms usually peak approximately four hours after each dose of IL-2 and worsen with further treatment. The decreased systemic vascular resistance may not return to normal for up to six days after IL-2 has been discontinued [
         <a href="#rid86">
          86
         </a>
         ]. It is not known whether the decrease in peripheral vascular resistance is a direct or indirect effect of IL-2.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IL-2 also is associated with direct myocardial toxicity although the mechanism of this is unclear. In patients with underlying coronary artery disease, ischemia, myocardial infarction, arrhythmias, and death have been reported [
         <a href="#rid87">
          87
         </a>
         ]. Ventricular and supraventricular arrhythmias have been reported to occur in 6 to 21 percent of patients [
         <a href="#rid86">
          86,88,89
         </a>
         ]. This is illustrated by a series of 199 patients in which 6 percent developed arrhythmias, including ventricular tachycardia, and 2.5 percent had elevated creatine kinase (CPK) isoenzyme MB levels [
         <a href="#rid89">
          89
         </a>
         ]. Supraventricular tachycardias were usually responsive to treatment [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          DIFFERENTIATION AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H40">
         <span class="h2">
          All-trans retinoic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">
          All-trans retinoic acid
         </a>
         (ATRA) is used to treat acute promyelocytic leukemia. Approximately 10 to 15 percent of patients develop the differentiation syndrome (previously called the "retinoic acid syndrome"), which can cause pericardial effusions (including the potential for cardiac tamponade) and myocardial ischemia/infarction. The differentiation syndrome is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">
          "Initial treatment of acute promyelocytic leukemia in adults", section on 'Administration and side effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H41">
         <span class="h2">
          Arsenic trioxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">
          Arsenic trioxide
         </a>
         (ATO) is used to treat acute promyelocytic leukemia. Serious adverse events attributed to treatment with ATO include the "differentiation syndrome," similar to that seen with ATRA, and cardiac abnormalities, including prolongation of the corrected QT (QTc) interval. These complications are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">
          "Initial treatment of acute promyelocytic leukemia in adults", section on 'ATO plus ATRA'
         </a>
         .)
        </p>
        <p>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc99b01b4-67ff-4793-8375-fe3a21c6c9be&amp;token=e9GIg5Sq5gSN0cFm1KptYAx8j%2BNHXF9fTJHOXX1undx6LHO8bgzVRjTtKRy6rZU1M2xXiHNiGihUos9hlKNBYbJiv8IjGwdFvYnlrR30WQyhWQllWufQRVpdVDI79KCu&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for ATO
         </a>
         recommends withholding the drug for a QTc interval &gt;450 msec in men and &gt;460 msec in women. Although the optimal way to calculate the QTc interval in patients receiving chemotherapy drugs that have the potential to alter the QTc interval is debated [
         <a href="#rid90">
          90,91
         </a>
         ], the original trial used the Framingham formula (
         <a class="calc calc_professional" href="/z/d/html/13459.html" rel="external">
          calculator 1
         </a>
         ) [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H42">
         <span class="h1">
          PROTEIN KINASE INHIBITORS
         </span>
        </p>
        <p class="headingAnchor" id="H2280057002">
         <span class="h2">
          Brigatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">
          Brigatinib
         </a>
         is a tyrosine kinase inhibitor (TKI) used in the treatment of patients with anaplastic lymphoma kinase (
         <em>
          ALK)
         </em>
         -positive metastatic non-small cell lung cancer (NSCLC). It is associated with both hypertension and bradycardia. Blood pressure and heart rate should be monitored regularly during treatment. If patients are symptomatic or have severe hypertension, brigatinib should be withheld, then dose reduced or permanently discontinued.
        </p>
        <p>
         In a phase II study, hypertension was reported in approximately 20 percent and bradycardia was noted in 7.6 percent of those receiving the recommended dose of
         <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">
          brigatinib
         </a>
         [
         <a href="#rid93">
          93,94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31948857">
         <span class="h2">
          Cobimetinib, trametinib, and binimetinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="105354" href="/z/d/drug information/105354.html" rel="external">
          Cobimetinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         inhibit mitogen-activated protein kinase (MEK). Cobimetinib and binimetinib are used, in conjunction with a BRAF inhibitor, for the treatment of advanced, metastatic or unresectable,
         <em>
          BRAF
         </em>
         -mutated melanoma. There is an increased risk for cardiomyopathy in patients receiving dual therapy with either cobimetinib and
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         or binimetinib and
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         compared with a single-agent BRAF inhibitor, and baseline left ventricular ejection fraction (LVEF) should be evaluated prior to initiation of these agents, after one month of treatment, and every two to three months thereafter [
         <a href="#rid95">
          95,96
         </a>
         ]. (See
         <a class="local">
          'Vemurafenib and encorafenib'
         </a>
         below.)
        </p>
        <p>
         In clinical trials of
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         in patients with metastatic melanoma, left ventricular dysfunction has been seen in up to 11 percent of treated patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase II trial in which all 97 patients underwent assessment of LVEF at baseline, at week 4, and every 12 weeks thereafter, three patients (3 percent) developed asymptomatic and reversible grade 3 LVEF reduction [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase III trial comparing
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         versus chemotherapy with
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         or
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         , 14 of the 211 patients who received at least one dose of trametinib developed cardiac toxicity (7 percent), 11 developed a decreased LVEF, and three had left ventricular dysfunction [
         <a href="#rid98">
          98
         </a>
         ]. Cardiomyopathy resolved in 10 of the 14, but four patients had serious cardiac-related events that were considered to be drug related and led to permanent discontinuation of the study drug [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Across clinical trials of
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         at the recommended dose, approximately 11 percent of patients developed evidence of cardiomyopathy (a decrease in LVEF below the institutional lower limits of normal with an absolute decrease in LVEF ≥10 percent below baseline), and 5 percent developed a decrease in LVEF below the institutional lower limits of normal with an absolute decrease in LVEF of ≥20 percent below baseline [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the PHAROS trial, LVEF decline below institutional lower limit of normal, with an absolute decrease in LVEF ≥10 percent, occurred in 11 percent of patients receiving
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         and
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         . Grade 3 LV dysfunction occurred in 1 percent of patients. Cardiomyopathy resolved in 82 percent of patients receiving the combination [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D0002ad27-779d-42ab-83b5-bc65453412a1&amp;token=T68o8mlcliPDZY2b7XwmuI3hgwW%2BBDlcns%2FQinTihLzYPVpelj5TbnxFYjhpc58OasY32O7M2vKkBQGe9tZnBXpy5CS5VmwNXOVp%2BSuVwNIA5g9RT711PrJiE57tVej5&amp;TOPIC_ID=2812" target="_blank">
          US
         </a>
         Food and Drug Administration (FDA) recommends the following, in regards to management of cardiotoxicity on
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         or
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         [
         <a href="#rid95">
          95,96
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess LVEF before initiation of therapy, at one month after treatment initiation, and then at two- to three-month intervals during treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Withhold treatment if the absolute LVEF decreases by 10 percent from pretreatment values to less than the institutional lower limit of normal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Permanently discontinue for symptomatic heart failure, any absolute decrease in LVEF of &gt;20 percent from baseline that is below the institutional lower limit of normal, and a persistent LVEF decrease of ≥10 percent from baseline that does not resolve within four weeks.
        </p>
        <p>
        </p>
        <p>
         Prolongation of the corrected QT (QTc) interval is reported with
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         . (See
         <a class="local">
          'Vemurafenib and encorafenib'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H31948627">
         <span class="h2">
          Crizotinib and ceritinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">
          Crizotinib
         </a>
         and
         <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">
          ceritinib
         </a>
         are orally active inhibitors of the anaplastic lymphoma kinase (ALK); they are both approved for treatment of advanced or metastatic non-small cell lung cancer (NSCLC) if the tumor contains a characteristic EML4-ALK fusion oncogene. (See
         <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">
          "Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Ceritinib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">
          "Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Crizotinib'
         </a>
         .)
        </p>
        <p>
         Sinus bradycardia is common in patients receiving these agents and can be profound, although it is generally asymptomatic and not associated with other events such as other arrhythmias:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In two trials evaluating the efficacy of
         <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">
          crizotinib
         </a>
         for advanced NSCLC, bradycardia was reported in only 12 of 240 patients who were assessable for treatment-related toxicity; all were mild (grade 1 or 2) in severity [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another report of 42 patients receiving treatment with
         <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">
          crizotinib
         </a>
         for advanced NSCLC, there was an average decrease of 26 bpm among all patients; 69 percent had at least one episode of sinus bradycardia (heart rate &lt;60 beats per minute [bpm]) [
         <a href="#rid101">
          101
         </a>
         ]. Profound sinus bradycardia (heart rate &lt;50 bpm) developed in 13 (31 percent). None of the patients who developed bradycardia during treatment were symptomatic or had electrocardiographic (ECG) changes such as QTc interval prolongation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less information is available with regard to
         <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">
          ceritinib
         </a>
         . In one report of 255 patients receiving ceritinib, bradycardia (heart rate &lt;50 bpm) was reported as a new finding in only 1 percent [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The United States Prescribing Information for both
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F202570s027lbl.pdf&amp;token=uPeHrS1y3Yye%2Fp2Z0scVTaV2qRwLK%2BTCtUtb2OUt3woo5dhi7GB0Vf5TVC7Ga7fszYrHjf05gorLml4gJTIYRHzmx0b95GNE0LaOOBbU5IA%3D&amp;TOPIC_ID=2812" target="_blank">
          crizotinib
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2014%2F205755lbl.pdf&amp;token=DQRBrKmwzM1eQcNI1ZSJirQZoBP6nx9ntCPPH6aI8oOSPLe0eZGUUJ1pzrsj5QA3gIxFcdWaYd7ZiodiPlibRX2H%2BnpfzQWrvlVK8zllV1c%3D&amp;TOPIC_ID=2812" target="_blank">
          ceritinib
         </a>
         recommends avoiding use in patients who are using other agents known to cause bradycardia (eg, beta-blockers,
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , nondihydropyridine calcium channel blockers,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ), and that heart rate and blood pressure be monitored regularly during therapy. Dose adjustment guidelines in the setting of symptomatic bradycardia are also provided.
        </p>
        <p class="bulletIndent1">
         In addition to bradycardia, QTc interval prolongation has been observed with both drugs, although it is uncommon. Three percent of 255 patients treated with
         <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">
          ceritinib
         </a>
         experienced a QTc interval increase over baseline of 60 msec; in a larger population of 304 patients treated with the drug, only one (&lt;1 percent) developed a QTc interval of &gt;500 msec [
         <a href="#rid102">
          102
         </a>
         ]. The US prescribing information for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F202570s027lbl.pdf&amp;token=uPeHrS1y3Yye%2Fp2Z0scVTaV2qRwLK%2BTCtUtb2OUt3woo5dhi7GB0Vf5TVC7Ga7fszYrHjf05gorLml4gJTIYRHzmx0b95GNE0LaOOBbU5IA%3D&amp;TOPIC_ID=2812" target="_blank">
          crizotinib
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2014%2F205755lbl.pdf&amp;token=DQRBrKmwzM1eQcNI1ZSJirQZoBP6nx9ntCPPH6aI8oOSPLe0eZGUUJ1pzrsj5QA3gIxFcdWaYd7ZiodiPlibRX2H%2BnpfzQWrvlVK8zllV1c%3D&amp;TOPIC_ID=2812" target="_blank">
          ceritinib
         </a>
         recommends avoiding both drugs in patients with congenital long QT syndrome and that patients with heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking other medications known to prolong the QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ) undergo periodic monitoring with ECGs and assessment of serum electrolytes. Treatment interruption and dose reduction is advised if QTc interval exceeds &gt;500 msec during treatment, with permanent discontinuation if it recurs or is accompanied by an arrhythmia, heart failure, hypotension, shock, syncope, or torsade de pointes.
        </p>
        <p>
        </p>
        <p>
         Given that both drugs are CYP3A4 substrates, they should be used with caution in patients who are receiving other drugs that inhibit CYP3A4  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Practice is variable regarding cardiac monitoring during therapy, however, some clinicians perform a baseline ECG for patients starting
         <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">
          crizotinib
         </a>
         or
         <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">
          ceritinib
         </a>
         only if they have known history of heart failure or cardiac arrhythmia issues, and check ECGs during therapy if bradycardia (symptomatic or not) develops or if the patient is started on another drug with known side effect of QTc prolongation. (See
         <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">
          "Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Management of toxicities associated with ALK inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3859595873">
         <span class="h2">
          BTK inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="140692" href="/z/d/drug information/140692.html" rel="external">
          pirtobrutinib
         </a>
         are orally active inhibitors of the Bruton tyrosine kinase; they are used for a variety of B-cell hematologic malignancies, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell and marginal zone lymphoma. All three drugs have been associated with cardiotoxicity. However, the later-generation BTK inhibitors (zanubrutinib, acalabrutinib, pirtobrutinib) demonstrate greater BTK selectivity and less off-target inhibition than ibrutinib, and this has translated into lower rates of cardiotoxicity. (See
         <a class="medical medical_review" href="/z/d/html/83749.html" rel="external">
          "Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">
          "Treatment and prognosis of Waldenström macroglobulinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">
          "Treatment of relapsed or refractory mantle cell lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4731.html" rel="external">
          "Splenic marginal zone lymphoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ibrutinib
         </strong>
         – Several cardiovascular toxicities have been reported with
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         , including supraventricular arrhythmias, ventricular arrhythmias, heart failure, conduction disorders, hypertension, and sudden death. The following data are available regarding overall risk:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A review of the World Health Organization's global database of individual case safety reports among 13,572 patients receiving
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         revealed reports of supraventricular arrhythmias in 959 (7 percent), heart failure in 363 (2.7 percent), ventricular arrhythmias in 70 (0.5 percent), cardiac conduction disorders in 50 (0.4 percent), and hypertension in 295 (2.2 percent) [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a multi-institutional series of 562 consecutive patients treated with
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         for B-cell malignancies, 78 percent of ibrutinib users developed new or worsened hypertension during therapy, and the development of hypertension was associated with a twofold higher risk of other major adverse cardiovascular events [
         <a href="#rid104">
          104
         </a>
         ]. Atrial fibrillation was the most common cardiovascular complication, occurring in 13 percent; this was followed by new heart failure (3.7 percent), myocardial infarction (MI, 1.4 percent), and ventricular arrhythmias or sudden cardiac death (1.1 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Another population-based cohort study of 778 pairs of ibrutinib-treated and unexposed patients with chronic lymphocytic leukemia revealed a higher three-year incidence of atrial fibrillation (23 versus 12 percent) and heart failure (7.7 versus 3.6 percent) with
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         , but no increase in risk of acute MI [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Data are also available from a safety analysis of four randomized trials of
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         for B-cell malignancies (756 patients receiving ibrutinib); cardiac disorders developed in 15 percent, the most common of which was atrial fibrillation (6 percent), which was grade 3 or 4 in 3 percent [
         <a href="#rid106">
          106
         </a>
         ]. The greatest risk was during the first three months of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         According to the updated
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F205552s035%2C215063s011lbl.pdf&amp;token=PZ7kvI20CqplU9tMZnSZlEJS4%2F0dWi3aOgN6TeJ7j2hYAL614q9YywNt4WqT3AGyLIa4CyLaUys3hMnSriOJaf9uHatoGP3%2FrehvFtx8gPNnD%2FeCVlQkgd76q7XOwYWY&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for ibrutinib
         </a>
         , these events have occurred particularly in patients with cardiac risk factors, including hypertension, diabetes mellitus, acute infection, and a previous history of cardiac arrhythmias. Specific dose reduction guidelines are provided for patients who develop grade 2 cardiac failure  (
         <a class="graphic graphic_table graphicRef58345" href="/z/d/graphic/58345.html" rel="external">
          table 3
         </a>
         ) or a symptomatic cardiac arrhythmia for which urgent intervention is needed (ie, grade 3) during therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Zanubrutinib
         </strong>
         – Although less cardiotoxic than
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         has also been associated with atrial flutter and atrial fibrillation (approximately 3 to 4 percent), and hypertension (12 percent all grade, 3 percent grade 3 or 4) [
         <a href="#rid107">
          107
         </a>
         ]. According to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D3e08fe23-d70e-424c-bc51-1222e320f902&amp;token=gRXvHvFHZ79hsthOiHNggKiMAoAvQroZvZHv8Hr3sEdBAxXhNhdx8%2FOZK%2BG54kE4v5Duwx15HL1P5q6QSDINL87YBKzbELxoyPX%2FoAQbHWm2D1cmKtt77Wz6VWnMSmZb&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for zanubrutinib
         </a>
         , patients with cardiac risk factors, hypertension, and acute infection may be at increased risk. Grade ≥3 ventricular arrhythmias have been reported in 0.2 percent of patients [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acalabrutinib
         </strong>
         – Across clinical trials of
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         , atrial fibrillation/flutter was reported in 4 percent of patients overall, and was grade 3 in 1.1 percent [
         <a href="#rid108">
          108
         </a>
         ]. According to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Ddd4835ef-e1bc-4997-a399-1ffa2556fbfe&amp;token=7aHfQNp1eDRfFVmdgSNirZTqs1rwpXgvaCKpEh8yMtVTzd0a21chvQW8vmhHaucvwiNFKqmYbm8O90y0rufEoHDUmvQKQE9YXBp9b8ZUrk4Bj3VbgFq6NlArlCpnmKw8&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for acalabrutinib
         </a>
         , patients with cardiac risk factors, hypertension, and acute infection may be at increased risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk for ventricular arrhythmias also appears to be elevated in patients treated with
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         . In a series of 290 consecutive patients treated with acalabrutinib over a six-year period, the overall risk was low (eight cases of incident ventricular arrhythmias [ventricular fibrillation, ventricular tachycardia, or symptomatic premature ventricular contractions] and one sudden death, 3 percent), this represented an eightfold higher relative risk for ventricular arrhythmias relative to similar aged non-BTK inhibitor treated individuals [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pirtobrutinib
         </strong>
         – In a clinical trial in 583 patients treated with
         <a class="drug drug_general" data-topicid="140692" href="/z/d/drug information/140692.html" rel="external">
          pirtobrutinib
         </a>
         , atrial fibrillation or flutter were reported in 2.7 percent of patients [
         <a href="#rid110">
          110
         </a>
         ], with grade 3 or 4 atrial fibrillation or flutter noted in 1 percent. Patients with cardiac risk factors (eg, hypertension or previous arrhythmia) may be at higher risk.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3087791603">
         <span class="h2">
          Agents targeting BCR::ABL1
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         , a small-molecule inhibitor of BCR::ABL1, KIT, PDGFR, and the SRC family of tyrosine kinases, is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), which is characterized by the BCR::ABL1 fusion protein, which functions as a tyrosine kinase, and gastrointestinal stromal tumors (GIST), which are characterized by mutations in
         <em>
          KIT
         </em>
         or
         <em>
          PDGFR
         </em>
         genes. Adverse cardiac events in patients receiving imatinib are likely mediated by inhibition of ABL1 [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite an early report of heart failure in patients treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         for Ph+ CML [
         <a href="#rid111">
          111
         </a>
         ], subsequent reports indicate &lt;2 percent incidence of clinically significant heart failure in CML clinical trial settings [
         <a href="#rid113">
          113
         </a>
         ]. Patients receiving imatinib for treatment of GIST have not been reported to have an increased risk for heart failure or left ventricular dysfunction [
         <a href="#rid114">
          114-116
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Side effects and their management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Imatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, the cardiac consequences of long-term
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         therapy remain unknown. Importantly, none of these reports were based on studies in which cardiac function was prospectively monitored. Assessment was based primarily on adverse event reports, which may not reflect the true incidence of cardiac disease. In the only study to prospectively assess left ventricular function in 59 patients with CML who were treated with imatinib, there was no evidence of deterioration over the initial 12 months [
         <a href="#rid117">
          117
         </a>
         ]. In the lone prospective study in which patients receiving imatinib for GIST were monitored with serum levels of brain natriuretic peptide (BNP), 2 of 55 patients followed over a three-month period had substantial increases in BNP (4 percent), suggesting the possibility of subclinical heart failure [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information from well-designed prospective studies with objective cardiac monitoring is needed to determine the incidence and clinical significance of heart failure attributable to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , both in patients with CML and GIST. Until then, some have suggested that patients receiving imatinib for either CML or GIST be thought of as stage A heart failure patients (ie, at risk for heart failure), but without structural heart disease or symptoms [
         <a href="#rid116">
          116,119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some have suggested that patients receiving these drugs be treated as "stage A" heart failure patients (ie, at risk for heart failure), but without structural heart disease or symptoms [
         <a href="#rid119">
          119
         </a>
         ]. Year 2013 guidelines for management of stage A heart failure from the AHA suggest that it may be reasonable to evaluate those who are receiving potentially cardiotoxic agents such as
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         for left ventricular dysfunction [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, obtaining a baseline assessment of LVEF in all patients receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (particularly for GIST where it is not even clear that there is a risk of cardiotoxicity) is not supported by compelling data. In our view, patients receiving imatinib should be monitored for signs and symptoms of heart failure, and clinicians should have a low threshold for formal assessment of left ventricular dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Guidelines for management of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         toxicity from the National Comprehensive Cancer Network (NCCN) suggest only that patients with cardiac disease or risk factors for heart failure who are receiving imatinib be monitored carefully, and that any patient with signs or symptoms consistent with heart failure be evaluated and treated [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We agree with these guidelines, and do not obtain a baseline assessment of LVEF prior to starting
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nilotinib
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          dasatinib
         </strong>
         <strong>
          , and
         </strong>
         <strong>
          bosutinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          Nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         are three second-generation multitargeted TKIs that are used for the treatment of Ph+ CML; all target the ATP binding site of BCR::ABL1, while nilotinib also targets KIT and PDGFR; dasatinib targets KIT, PDGFR, and the SRC family of kinases; and bosutinib targets the SRC family of tyrosine kinases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cardiac effects have been described with each of these agents:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All three drugs have been associated with QT prolongation [
         <a href="#rid91">
          91,122,123
         </a>
         ]. Abnormalities in potassium and magnesium levels must be corrected prior to drug initiation, other drugs that may affect the QTc interval should be avoided, caution should be used in patients at risk for QT interval prolongation, and serial ECGs should be followed. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Other toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The optimal way to calculate the QTc interval in patients receiving chemotherapy drugs that have the potential to alter the QTc interval is debated [
         <a href="#rid90">
          90,91
         </a>
         ]; the United States Prescribing Information for any of the three drugs does not specify which correction formula to use (
         <a class="calc calc_professional" href="/z/d/html/13459.html" rel="external">
          calculator 1
         </a>
         ). Use of the Framingham formula has been suggested by one group [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although a definite causal relationship has not been established,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         has also been associated with chest pain, pericardial effusion, ventricular dysfunction, and heart failure [
         <a href="#rid124">
          124
         </a>
         ]. The United States Prescribing Information states that 1.6 percent of 258 patients taking dasatinib developed cardiomyopathy, heart failure, diastolic dysfunction, fatal myocardial infarction, and/or left ventricular dysfunction [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although clinical heart failure is not described, fluid retention occurs with
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         and may manifest as pericardial effusion or pulmonary edema [
         <a href="#rid125">
          125
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/774.html" rel="external">
          "Cardiotoxicity of trastuzumab and other HER2-targeted agents", section on 'Lapatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ponatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         is a third generation BCR::ABL1 TKI with activity against CML with a
         <em>
          T3151
         </em>
         mutation; it is approved for treatment of patients with CML or acute lymphoblastic leukemia who are resistant or unable to tolerate another TKI. Although the antitumor efficacy appears due to its inhibition of the tyrosine kinase BCR::ABL1, ponatinib also blocks several other receptor tyrosine kinases such as the VEGF receptor 2. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Ponatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         is associated with more cardiovascular toxicity than the prior generations of BCR::ABL1 TKIs. Cardiac toxicities include heart failure, ischemic heart disease due to arterial occlusive events, cardiac arrhythmias, QTc prolongation, and peripheral vascular events, both arterial and venous. Cardiovascular toxicity led to the drug being withdrawn from the market in 2013, but given the lack of alternative effective treatment option for CML resistant to other TKIs, it was reintroduced with added safety measures regarding cardiovascular risk. Since then, a newly approved agent,
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         (discussed below) is available and should be considered for treatment of patients with BCR::ABL1
         <em>
          T3151
         </em>
         who have high-risk for cardiovascular adverse events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The cardiovascular risks associated with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         can be summarized as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Arterial occlusive events (AOEs)
         </strong>
         – In the first analysis of the PACE trial the incidence of cardiovascular, cerebrovascular, and peripheral arterial vascular adverse events in patients treated with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         were 7.1, 3.6, and 4.9 percent, respectively [
         <a href="#rid126">
          126
         </a>
         ]. Of the 5 percent of patients who had a serious cardiovascular event, 55 percent had a history of ischemic disease at study enrollment, and 95 percent had one or more risk factors (hypertension, diabetes, hypercholesterolemia, or obesity) with or without a history of ischemic disease, nonischemic cardiac disease, or venous thromboembolism.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a later analysis of the trial with five-year follow-up, the cumulative incidence of any AOE was 26 percent, and vascular occlusive events appeared more frequently during the first and second year of treatment (14.5 and 14.1 percent, respectively) than afterward (10.5 percent during the third year, 7.2 percent thereafter) [
         <a href="#rid127">
          127
         </a>
         ]. Post hoc analysis suggested that these events might be dose dependent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, this could not be confirmed in the OPTIC study, which directly compared three daily doses of
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         (45 mg [standard], 30 mg, and 15 mg) in 283 adults with refractory CML [
         <a href="#rid128">
          128
         </a>
         ]. For patients who were initially assigned to 45 or 30 mg daily, the dose was reduced to 15 mg daily upon clinical response. The primary end point (response at 12 months) was achieved by more patients who received the initial 45 mg dose (44 versus 29 and 23 percent with 30 and 15 mg doses), but independently confirmed grade ≥3 AOEs were not more frequent with the higher initial dose (occurring in 5, 5, and 3 percent of those treated initially 45, 30, and 15 mg daily dose groups, respectively). The authors concluded that the optimal risk/benefit outcomes occurred with the 45 mg starting dose, which was reduced to 15 mg daily upon achievement of a response.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D16d804b6-4957-43ee-b18c-3b36ec37c5ac&amp;token=nsbS5wJ1GlqucnAGA7poM3kNGUyRdJarz6VRpayQi5EjOJV7XxYOx71RzaTCOfYpprifcxhl%2FflzxXHQND5vxXdFMKiPaug%2B2Tx6YjdIax9waRVDB6OX74D0w6TTQFvJ&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for ponatinib
         </a>
         recommends an assessment for whether the benefits of
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         are expected to exceed the cardiovascular risks prior to initiating therapy. They also suggest monitoring for evidence of AOEs during ponatinib therapy and provide guidance for dose modification based on recurrence/symptom severity. They also recommend that clinicians "consider" benefit-risk to guide a decision to restart the drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         One such tool that may be beneficial to ascertain the risk for AOEs with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         is a risk chart  (
         <a class="graphic graphic_table graphicRef134830" href="/z/d/graphic/134830.html" rel="external">
          table 4
         </a>
         ) that includes the Systematic COronary Risk Evaluation (SCORE) categories predicting 10-year cardiovascular mortality based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels, as defined in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.escardio.org%2FEducation%2FPractice-Tools%2FCVD-prevention-toolbox&amp;token=%2B0rEyHQ1T7gRoXXx698zArKc24%2FtAF%2FwAz8OHD1HlgMRSwaPpssyui0%2FpCswuGLdRpjh1jg12pXgxvX%2FNW8lcx1P7FDyD%2FvOaLSKt9yfBgE%3D&amp;TOPIC_ID=2812" target="_blank">
          2016 European guidelines on cardiovascular disease prevention in clinical practice
         </a>
         [
         <a href="#rid129">
          129-131
         </a>
         ]. Those patients with high to very high SCORE levels (ie, ≥10 percent) seem to be at the greatest risk of AOEs with ponatinib.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Heart failure
         </strong>
         – Potentially fatal heart failure has been reported with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In the OPTIC study described above, of the 94 patients initially treated with 45 mg daily, heart failure developed in 12 percent, and was severe in 1.1 percent [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In the PACE trial, heart failure occurred in 9 percent of the 449 patients; 7 percent were ≥grade 3 [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D16d804b6-4957-43ee-b18c-3b36ec37c5ac&amp;token=nsbS5wJ1GlqucnAGA7poM3kNGUyRdJarz6VRpayQi5EjOJV7XxYOx71RzaTCOfYpprifcxhl%2FflzxXHQND5vxXdFMKiPaug%2B2Tx6YjdIax9waRVDB6OX74D0w6TTQFvJ&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for ponatinib
         </a>
         recommends monitoring patients closely for signs and symptoms of heart failure, and provides recommendations for dose modification based on severity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiac arrhythmias
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Of the 94 patients who received a starting dose of 45 mg daily in the OPTIC trial, cardiac arrhythmias developed in 15 percent; 4.3 percent experienced grade 3 or 4 cardiac arrhythmias (which included atrial fibrillation, cardiorespiratory arrest, supraventricular asystoles, and syncope) [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In the PACE trial, cardiac arrhythmias developed in 20 percent of the 449 patients; 7 percent experienced grade 3 or 4 arrhythmias. Atrial fibrillation was the most frequent (8 percent, 3.3 percent grade 3 or 4), but ventricular arrhythmias occurred in 3.4 percent (with only one event being grade 3 or 4). Other grade 3 or 4 arrhythmia events included syncope, tachycardia (including ventricular tachycardia) and bradycardia, QTc interval prolongation, atrial flutter, complete AV block, cardio-respiratory arrest, loss of consciousness, and sinus node dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D16d804b6-4957-43ee-b18c-3b36ec37c5ac&amp;token=nsbS5wJ1GlqucnAGA7poM3kNGUyRdJarz6VRpayQi5EjOJV7XxYOx71RzaTCOfYpprifcxhl%2FflzxXHQND5vxXdFMKiPaug%2B2Tx6YjdIax9waRVDB6OX74D0w6TTQFvJ&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information
         </a>
         recommends closely monitoring for signs and symptoms suggestive of a slow heart rate (fainting, dizziness) or rapid heart rate (chest pain, palpitations, dizziness), and provides recommendations for dose modifications based on severity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mechanisms
         </strong>
         – Underlying mechanisms for cardiotoxicity associated with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         are not completely understood. Ponatinib may exert its cardiotoxic effects by inhibition of growth signaling pathways that are known to regulate cardiomyocyte survival and maintain cardiac homeostasis [
         <a href="#rid132">
          132
         </a>
         ]. Off-target actions on platelet activation and/or endothelial cell function through targeting of VEGF receptors or drug-induced thrombotic microangiopathy may also contribute to the development of AOEs [
         <a href="#rid133">
          133-135
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention and management
         </strong>
         – The US Food and Drug Administration and the European Medicine Agency recommend that the cardiovascular profile of patients who are candidates for
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         should be carefully evaluated. For patients deemed to carry a high risk of cardiovascular events, other life-saving therapeutic options should be considered. When alternative options are not available, treatment with ponatinib is indicated but requires that hematologists and cardiologists collaborate and identify modalities of surveillance and risk mitigation in the best interest of the patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Several guidelines regarding
         <strong>
         </strong>
         the identification, prevention, and management of cardiovascular
         <strong>
         </strong>
         adverse events in CML patients on
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         are published [
         <a href="#rid129">
          129,136-140
         </a>
         ]. Algorithmic approaches to cardiovascular screening of patients undergoing therapy with potentially cardiotoxic TKIs have been proposed [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asciminib
         </strong>
         –
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          Asciminib
         </a>
         is also used for treatment of Ph+ CML refractory to ≥2 prior treatments or Ph+ CML with a
         <em>
          T315I
         </em>
         mutation; it targets BCR::ABL1, but by a different mechanism than the other four drugs described above. Asciminib is a first-in-class STAMP (Specifically Targeting the ABL1 Myristoyl Pocket) inhibitor with the potential to overcome resistance or intolerance to other approved TKIs. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         Cardiovascular toxicity (including ischemic cardiac, central nervous system, and arterial thromboembolic conditions ) and heart failure occurred in 46 (13 percent) and 8 (2.2 percent) of 356 patients receiving the drug, respectively, and fatalities were reported [
         <a href="#rid141">
          141
         </a>
         ]. Arrhythmias, including prolongation of the QTc interval, occurred in 23 patients (7 percent). Mostly, cardiovascular toxicity has occurred in patients with preexisting risk factors, and/or prior exposure to multiple TKIs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F215358s000Orig1lbl.pdf&amp;token=oY%2BbRdGQm1xxL5NkJlgyG6njZkhzpIgOKo9g62tCdpKuKBxVodHg5GDLjLlEr6QWj9s9OcrxsnTAp9l9AnScitKSCR8nvhOStMhwtc9df0i%2FGhAc8JLDOGyqBcGu5fBz&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for asciminib
         </a>
         recommends monitoring patients with a history of cardiovascular risk factors for cardiovascular signs and symptoms, and contains specific recommendation for dose modification for grade 3 or higher nonhematologic adverse reactions. There are no specific guidelines for monitoring serial ECGs during therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31948849">
         <span class="h2">
          Osimertinib and mobocertinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">
          Osimertinib
         </a>
         is a third-generation oral EGFR TKI that is active in non-small cell lung cancers harboring the EGFR T790M mutation. Decreases in LVEF of ≥10 percent from baseline to a level &lt;50 percent were observed in 3 to 5 percent of patients treated on two trials [
         <a href="#rid142">
          142,143
         </a>
         ] and in 3.9 percent of patients in a pooled population [
         <a href="#rid144">
          144
         </a>
         ] However, most events were asymptomatic and resolved without treatment of the event or discontinuation of osimertinib. Although causality remains uncertain, cardiac monitoring is advised with assessment of LVEF at baseline and every three months on treatment [
         <a href="#rid145">
          145
         </a>
         ]. Additionally, patients with predisposition towards or history of QTc prolongation or those taking medications known to cause QTc prolongation should have monitoring of ECG and electrolytes while on osimertinib [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="132715" href="/z/d/drug information/132715.html" rel="external">
          Mobocertinib
         </a>
         is a third-generation oral EGFR TKI that is active in non-small cell lung cancers harboring the EGFR exon 20 insertion mutation. As with
         <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">
          osimertinib
         </a>
         , both reduced ejection fraction and prolongation of the QTc interval are reported with this agent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the pooled safety population of 250 patients treated with this agent who had electrocardiograms during treatment, 1.2 percent had a QTc interval &gt;500 msec, and 11 percent had a change-from-baseline QTc interval &gt;60 msec. One patient developed grade 4 torsades de pointes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac toxicity (decreased ejection fraction, cardiomyopathy, and heart failure) may be fatal. In this same pooled safety population, heart failure occurred in seven (2.7 percent), three cases were grade 3 or 4, and there was one fatality.
        </p>
        <p>
        </p>
        <p>
         The FDA recommends assessment of left ventricular ejection fraction, QTc interval, and electrolyte levels at baseline, and periodically during treatment; QTc should be assessed more frequently in patients with severe renal impairment [
         <a href="#rid145">
          145
         </a>
         ]. Electrolyte abnormalities should be corrected prior to initiating treatment. Concomitant treatment with drugs that are known to prolong the QTc interval or that are strong or moderate CYP3A inhibitors  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 2
         </a>
         ) should be avoided during treatment. There are also provisions for withholding, reducing the dose, or permanently discontinuing
         <a class="drug drug_general" data-topicid="132715" href="/z/d/drug information/132715.html" rel="external">
          mobocertinib
         </a>
         based on the severity of the QTc prolongation or heart failure during therapy.
        </p>
        <p class="headingAnchor" id="H2789693589">
         <span class="h2">
          Quizartinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="142055" href="/z/d/drug information/142055.html" rel="external">
          Quizartinib
         </a>
         is a kinase inhibitor approved for use in adults with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication-positive, in combination with
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="142055" href="/z/d/drug information/142055.html" rel="external">
          Quizartinib
         </a>
         has been associated with QT prolongation, Torsades de Pointes, and cardiac arrest. As such, the United States Prescribing Information recommends monitoring electrocardiograms and levels of serum electrolytes [
         <a href="#rid146">
          146
         </a>
         ]. In a clinical trial, QTc prolongation occurred in 14 percent with quizartinib compared with 4 percent with placebo; grade 3 or 4 QT prolongation occurred in 3 and 1.1 percent, respectively.
        </p>
        <p class="headingAnchor" id="H651723948">
         <span class="h2">
          Ribociclib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">
          Ribociclib
         </a>
         is one several kinase inhibitors that inhibit the cyclin-dependent kinase (CDK) 4/6 pathway. Ribociclib is approved for use in the treatment of hormone-positive, advanced or metastatic breast cancer. Prolongation of the QTc interval has been observed in patients receiving ribociclib. Typically, QTc prolongation occurred within the first four weeks of initiating drug therapy and was reversible with dose interruption.
        </p>
        <p>
         As a result, the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Daaeaef94-f3f5-4367-8ea2-b181d7be2da8&amp;token=iiNOOu08WSPGxVf%2BsDj%2BqH02wMDBK0BI2iHdDqZ8NUkvLo%2FeFircdzFh2Yzc1tepwFWTO1juuV%2BKnc8ZmPT5u8BygsFk1%2FcZb19S6hPmT7XUTn8V6QPtHSlzvmxbymo1&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for ribociclib
         </a>
         recommends that serum electrolytes be monitored prior to initiation and before each of the first six cycles. Abnormalities should be corrected prior to starting treatment. Additionally, an ECG is recommended prior to initiating therapy. Treatment should only be started if the QTc is &lt;450 msec. Although the optimal way to calculate the QTc interval in patients receiving chemotherapy drugs that have the potential to alter the QTc interval is debated [
         <a href="#rid90">
          90,91
         </a>
         ], the United States Prescribing Information specifically recommends use of the Fridericia formula (
         <a class="calc calc_professional" href="/z/d/html/13459.html" rel="external">
          calculator 1
         </a>
         ) for this drug.
        </p>
        <p>
         An ECG should be repeated at day 14 of cycle 1, at initiation of the second cycle, and thereafter as clinically indicated. QTc intervals &gt;480 msec require dose interruption. Specific management recommendations are outlined in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Daaeaef94-f3f5-4367-8ea2-b181d7be2da8&amp;token=iiNOOu08WSPGxVf%2BsDj%2BqH02wMDBK0BI2iHdDqZ8NUkvLo%2FeFircdzFh2Yzc1tepwFWTO1juuV%2BKnc8ZmPT5u8BygsFk1%2FcZb19S6hPmT7XUTn8V6QPtHSlzvmxbymo1&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for ribociclib
         </a>
         .
        </p>
        <p class="headingAnchor" id="H406736133">
         <span class="h2">
          Ripretinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          Ripretinib
         </a>
         is a kinase inhibitor of KIT and PDGFRA that is approved as a fourth-line agent for treatment of advanced gastrointestinal stromal tumors; in vitro, it also inhibits VEGFR2. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Ripretinib'
         </a>
         .)
        </p>
        <p>
         The following data are available regarding cardiotoxicity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the phase III INVICTUS trial, cardiac failure occurred in 1.2 percent of the 85 patients who received
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         ; of the 77 who had a baseline and at least one postbaseline echocardiogram, grade 3 decreased ejection fraction  (
         <a class="graphic graphic_table graphicRef128231" href="/z/d/graphic/128231.html" rel="external">
          table 5
         </a>
         ) developed in 2.6 percent [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a pooled safety population of 351 patients, cardiac dysfunction (heart failure, acute left ventricular failure, diastolic dysfunction, and ventricular hypertrophy) occurred in 1.7 percent, and the adverse reactions were grade 3 in 1.1 percent [
         <a href="#rid148">
          148
         </a>
         ]. Of the patients who had a baseline and at least one post-treatment echocardiogram, grade 3 decreased ejection fraction  (
         <a class="graphic graphic_table graphicRef128231" href="/z/d/graphic/128231.html" rel="external">
          table 5
         </a>
         ) occurred in 3.4 percent.
        </p>
        <p>
        </p>
        <p>
         Whether these reflect inhibition of VEGFR2, KIT, PDGFRA, or a combination of these targets remains unclear. Several other antiangiogenic TKIs are associated with left ventricular dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Specific VEGFR tyrosine kinase inhibitors'
         </a>
         .)
        </p>
        <p>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F213973s000lbl.pdf&amp;token=vLExsDq09gOufMQh7QKEZoWLVeAIPmP3isBzGS4KDECSZnZq2lcg12INvzWi0izUgr0oyxdIVyLiyD7b611bc7mSKDD1a%2FF%2FW%2B%2BKps6nFE8%3D&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for ripretinib
         </a>
         recommends a baseline echocardiogram or multigated acquisition (MUGA) scan prior to initiation of therapy and as clinically indicated afterwards;
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         should be discontinued in those who develop grade ≥3 left ventricular diastolic dysfunction on treatment. There are no data on safety of this drug in those with a baseline ejection fraction &lt;50 percent.
        </p>
        <p class="headingAnchor" id="H174239516">
         <span class="h2">
          Selpercatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          Selpercatinib
         </a>
         is a kinase inhibitor approved to treat non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers that have an alteration (mutation or fusion) in the specific rearranged during transfection gene (
         <em>
          RET
         </em>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">
          "Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'RET rearrangements'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy", section on 'Selpercatinib'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          Selpercatinib
         </a>
         can cause concentration-dependent prolongation in the corrected QT interval (QTc). In clinical trials, an increase in the QTc interval to &gt;500 ms was measured in 6 percent of patients, and an increase in the QTc interval of at least 60 ms over baseline was measured in 15 percent of patients [
         <a href="#rid149">
          149
         </a>
         ]. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F213246s000lbl.pdf&amp;token=P5vVCfUWIePIxL%2FJ3RfcLgZ2whMtquSz5n61dhfsNnlUGEFi6dL8kDr9IPAVwTFaE0M7leIgDHbR4WdtMFA1BGZjfhnS%2F7UmloOgtHhQM8A%3D&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information
         </a>
         recommends that clinicians assess QT interval, electrolytes, and thyroid-stimulating hormone (TSH) at baseline and periodically during treatment, adjusting frequency based upon risk factors including diarrhea, and that hypokalemia, hypomagnesemia, and hypocalcemia be corrected prior to initiating and during treatment.
        </p>
        <p>
         The QT interval should be monitored more frequently when
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          selpercatinib
         </a>
         is administered concomitant with strong and moderate CYP3A inhibitors  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 2
         </a>
         ) or other drugs known to prolong QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1049342833">
         <span class="h2">
          Sorafenib and sunitinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          Sorafenib
         </a>
         and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         are orally active multi-targeted TKIs that are used for the treatment of metastatic renal cell carcinoma. In addition, sorafenib is used in the treatment of advanced hepatocellular cancer, and sunitinib is used for imatinib-refractory gastrointestinal stromal tumors (GIST) and for advanced pancreatic neuroendocrine tumors. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Sunitinib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">
          "Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Sunitinib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma", section on 'Sorafenib'
         </a>
         .)
        </p>
        <p>
         In clinical trials, both drugs have been associated with a small but definite risk of hypertension and cardiotoxicity.
        </p>
        <p>
         However, a major problem with defining the precise rate of cardiotoxicity associated with both drugs (and its reversibility) is that phase III trials have not pursued cardiac endpoints, and the identification of cardiac side effects with both drugs has predominantly been based on the occurrence of clinical symptoms. Further detailed prospective study of cardiotoxicity of these agents is needed. This subject is addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Left ventricular dysfunction and myocardial ischemia'
         </a>
         .)
        </p>
        <p>
         In addition to declines in LVEF and clinical heart failure, reported ECG changes have included changes in rhythm, conduction disturbance, change in axis or QRS amplitude, ST or T wave changes, and QTc prolongation with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Prolongation of the QTc interval and cardiac arrhythmias'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2305505417">
         <span class="h2">
          Vandetanib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">
          Vandetanib
         </a>
         is an orally active multi-targeted TKI that inhibits epidermal growth factor reception (EGFR), vascular endothelial growth factor (VEGF), rearranged during transfection (RET), protein tyrosine kinase 6 (BRK), TIE2, EPH kinase receptors, and SRC kinase receptors, selectively blocking intracellular signaling, angiogenesis, and cellular proliferation. It is used mainly for treatment of medullary thyroid cancer. In clinical trials, vandetanib has been associated with prolongation of the QTc interval, torsades de pointes, and sudden death. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Specific VEGFR tyrosine kinase inhibitors'
         </a>
         .)
        </p>
        <p>
         Because of the risk of cardiotoxicity, the United States Prescribing Information includes a black box warning to correct hypocalcemia, hypokalemia, and/or hypomagnesemia prior to drug administration. In addition, given the long half-life of the drug (19 days), ECGs are recommended to monitor the QT interval at baseline, at two to four weeks, 8 to 12 weeks after starting treatment, and every three months thereafter. Monitoring of serum potassium, calcium, and magnesium levels as well as TSH is recommended on the same schedule. Concurrent administration of drugs known to prolong the QTc interval should be avoided  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ). Largely because of the cardiovascular risk,
         <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">
          vandetanib
         </a>
         is only available through a restricted distribution program (the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.caprelsarems.com%2Findex.asp&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLE4VwEy4SEyHgSiAJI0FL2khNK%2F4KwfzF%2FFqaC3%2BIiVo&amp;TOPIC_ID=2812" target="_blank">
          Vandetanib Risk Evaluation and Mitigation Strategy [REMS] Program
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy", section on 'Vandetanib'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31948445">
         <span class="h2">
          Vemurafenib and encorafenib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          Vemurafenib
         </a>
         and
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         are orally available inhibitors of some mutated forms of
         <em>
          BRAF
         </em>
         that are approved for treatment of metastatic melanoma with a V600E
         <em>
          BRAF
         </em>
         mutation. (See
         <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">
          "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">
          "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'
         </a>
         .)
        </p>
        <p>
         Both drugs have been associated with prolongation of the QTc interval. The United States Prescribing Information for
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         recommends that the drug not be given to patients with congenital long QTc syndrome or to those who are receiving other drugs that prolong the QT interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ). Furthermore, it is recommended that ECGs and electrolytes be monitored before treatment and after dose modification. For patients starting therapy with vemurafenib, ECGs are recommended at day 15, monthly during the first three months of treatment, every three months thereafter, and more often as clinically indicated. If the QTc interval exceeds 500 msec, treatment should be temporarily interrupted, and electrolyte abnormalities should be sought and corrected.
        </p>
        <p>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D235dfc38-0f0b-4037-b501-7a9f4294740c&amp;token=cz2Z670w5QAjJDIZELfCDdJMMIlO6GSt%2FTFnYGfTXAUQPijco2jJMhi%2FDDrKU6iptbkhVid4%2F8hDNx3vAYS3Vu0rIJ5mXCrY0Fku1vUcR4a6EwktLB2PhcvjjRYVvbqx&amp;TOPIC_ID=2812" target="_blank">
          United States Prescribing Information for encorafenib
         </a>
         does not provide a specific recommendation about how often to monitor ECGs during therapy but recommends the following for managing prolongations in QTc during therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Corrected QT by Fridericia/Framingham (QTcF) &gt;500 msec, and ≤60 msec increase from baseline – Withhold
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         until the QTcF is ≤500 msec, then resume at a reduced dose. If there is more than one recurrence, permanently discontinue encorafenib.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         QTcF &gt;500 msec, and &gt;60 msec increase from baseline – Permanently discontinue
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         The optimal way to calculate the QTc interval in patients receiving chemotherapy drugs that have the potential to alter the QTc interval is debated [
         <a href="#rid90">
          90,91,150
         </a>
         ]. The United States Prescribing Information is ambiguous, using the term "QTcF" for
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         , which is undefined and could refer to the Framingham or Fridericia correction (
         <a class="calc calc_professional" href="/z/d/html/13459.html" rel="external">
          calculator 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management", section on 'ECG findings'
         </a>
         .)
        </p>
        <p>
         Use of
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         with
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         is discussed above. (See
         <a class="local">
          'Cobimetinib, trametinib, and binimetinib'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H48">
         <span class="h1">
          MISCELLANEOUS AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H49">
         <span class="h2">
          Diethylstilbestrol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diethylstilbestrol (DES) is a synthetic estrogen that was used to treat advanced prostate cancer and breast cancer. Multiple studies demonstrated an increased risk of cardiovascular death in patients treated with DES. This agent is no longer commercially available in the United States. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H165748358">
         <span class="h2">
          LHRH agonist/antagonist
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increasingly more attention is being given to the potential cardiovascular toxicities associated with long-term androgen deprivation using luteinizing hormone releasing hormone (LHRH) agonists and antagonists and antiandrogen therapies. To date, conflicting data exist regarding cardiovascular toxicity of manipulation of the androgen axis. This subject is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">
          "Side effects of androgen deprivation therapy", section on 'Potential cardiovascular harm'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H51">
         <span class="h2">
          Serotonin antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although usually well tolerated, the serotonin receptor antagonists often used during chemotherapy as antiemetics have some potential for cardiac effects, notably corrected QT (QTc) prolongation [
         <a href="#rid151">
          151
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">
          "Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Cardiac issues'
         </a>
         .)
        </p>
        <p>
         Clinical trials in healthy subjects and patients undergoing chemotherapy have demonstrated transient asymptomatic electrocardiographic (ECG) changes (increases in PR interval, QRS complex duration, and QTc interval) following administration of
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         ,
         <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">
          granisetron
         </a>
         , or
         <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">
          dolasetron
         </a>
         [
         <a href="#rid152">
          152-157
         </a>
         ]; chest pain has been attributed to ondansetron [
         <a href="#rid158">
          158
         </a>
         ]. Since almost all of these studies excluded patients with preexisting cardiac disease, the clinical significance of these events in such patients, particularly those receiving cardiac medications, is unknown.
        </p>
        <p class="headingAnchor" id="H7757908">
         <span class="h2">
          Proteasome inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          Bortezomib
         </a>
         and
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         are proteasome inhibitors that are used for the treatment of multiple myeloma.
        </p>
        <p>
         In clinical trials of
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         , a second-generation proteasome inhibitor, new onset or worsening of preexisting heart failure with decreased left ventricular function or myocardial ischemia has been reported in approximately 7 percent of patients, and deaths due to cardiac arrest have occurred within one day of drug administration [
         <a href="#rid159">
          159
         </a>
         ]. In addition, pulmonary arterial hypertension has been reported in 2 percent of patients treated with carfilzomib.
        </p>
        <p>
         In a phase II trial of 266 patients treated with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         monotherapy for relapsed myeloma, 10 experienced heart failure (3.8 percent), 4 had a cardiac arrest (1.5 percent), and 2 had a myocardial infarction during the study (0.8 percent) [
         <a href="#rid160">
          160
         </a>
         ]. The risk did not appear to be cumulative, at least through 12 cycles of therapy. However, the magnitude of the attributable risk, risk factors, and natural history, including reversibility, of carfilzomib-related cardiac toxicity remain incompletely characterized. Recommended dose modification based upon cardiac toxicity is available in the US prescribing information.
        </p>
        <p>
         Cardiotoxicity might represent a class effect, as heart failure events (acute pulmonary edema, cardiac failure, cardiogenic shock) have also been described in patients treated with
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         , a first-generation proteasome inhibitor [
         <a href="#rid161">
          161
         </a>
         ]. However, causality remains unclear, and the risk seems lower than with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase III trial comparing
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         versus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         for relapsed myeloma, the incidence of treatment-emergent cardiac disorders during treatment with bortezomib or dexamethasone was 15 and 13 percent, respectively; seven patients receiving bortezomib (2 percent) and eight patients receiving dexamethasone (2 percent) developed heart failure during the study [
         <a href="#rid162">
          162
         </a>
         ]. There were eight deaths thought to be possibly related to study drug; four in the bortezomib group (including three from cardiac causes and one from respiratory failure), and four in the dexamethasone group (three from sepsis and one from sudden death of unknown cause).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the multicenter PROTECT (Prospective Observation of Cardiac Safety with Proteasome Inhibitor) trial, conducted in patients treated for relapsed multiple myeloma, cardiovascular adverse events occurred in 51 percent of the 65 patients treated with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         and 17 percent of the 30 patients treated with
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         [
         <a href="#rid161">
          161
         </a>
         ]. In both groups, 86 percent of the cardiovascular adverse events occurred within the first three months. Interestingly, elevated levels of natriuretic peptides (BNP or N-terminal proBNP) occurring mid-first cycle of treatment with carfilzomib were associated with a substantially higher risk of adverse cardiovascular events (odds ratio 36). Validation of this finding is needed before assay of natriuretic peptides can be incorporated into the routine management of patients receiving carfilzomib.
        </p>
        <p>
        </p>
        <p>
         As with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         , cardiac dysfunction does not appear to be cumulative [
         <a href="#rid163">
          163
         </a>
         ].
        </p>
        <p>
         Abnormalities appear to be largely reversible with prompt cessation of therapy and initiation of traditional heart failure treatment [
         <a href="#rid164">
          164
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H52">
         <span class="h2">
          Histone deacetylase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reversible acetylation of histones, a family of nuclear proteins that interact with DNA, is an important mechanism by which gene expression is regulated. Removal of acetyl groups by histone deacetylase (HDAC) stabilizes the interaction between DNA and histones, repressing transcription. Inhibitors of HDAC re-acetylate histones, thereby reactivating transcription of dormant tumor-suppressor genes.
        </p>
        <p>
         Two HDAC inhibitors (
         <a class="drug drug_general" data-topicid="9491" href="/z/d/drug information/9491.html" rel="external">
          vorinostat
         </a>
         [suberoylanilide hydroxamic acid, SAHA] and
         <a class="drug drug_general" data-topicid="9536" href="/z/d/drug information/9536.html" rel="external">
          romidepsin
         </a>
         [depsipeptide]) are approved in the United States for the treatment of cutaneous T-cell lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/4759.html" rel="external">
          "Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Romidepsin'
         </a>
         .)
        </p>
        <p>
         Both drugs have been associated with transient ECG changes (including prolongation of the QTc interval  (
         <a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">
          waveform 1
         </a>
         ) and ST segment and T wave changes) in some but not all studies [
         <a href="#rid165">
          165-167
         </a>
         ]. Supraventricular and ventricular arrhythmias including nonsustained ventricular tachycardia are rare in patients receiving
         <a class="drug drug_general" data-topicid="9536" href="/z/d/drug information/9536.html" rel="external">
          romidepsin
         </a>
         , and evidence of acute or cumulative cardiac damage has not been seen [
         <a href="#rid165">
          165
         </a>
         ].
        </p>
        <p>
         Routine ECG monitoring is not recommended for either drug in the US prescribing information. However, both drugs should be used with caution in patients with significant heart disease, congenital long QT syndrome, and those who are receiving other drugs that prolong the QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ) or inhibit CYP3A4, which is the principal enzyme responsible for the metabolism of
         <a class="drug drug_general" data-topicid="9536" href="/z/d/drug information/9536.html" rel="external">
          romidepsin
         </a>
         and
         <a class="drug drug_general" data-topicid="9491" href="/z/d/drug information/9491.html" rel="external">
          vorinostat
         </a>
         (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid168">
          168
         </a>
         ]. In addition, serum potassium and magnesium levels should be in the normal range before drug administration since hypokalemia and hypomagnesemia predispose to arrhythmias.
        </p>
        <p class="headingAnchor" id="H53">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p>
         In contrast to anthracycline and anthracycline-like agents, efforts at prevention with molecularly targeted agents are in their infancy. (See
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity"
         </a>
         .)
        </p>
        <p>
         There are several reasons for this:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Molecularly targeted agents are generally newer drugs with less clinical experience with their toxicity or toxicity management than with anthracyclines. Furthermore, patients at the highest risk for developing such cardiac toxicity are often excluded from clinical trials evaluating efficacy and safety of mechanistically new anti-neoplastic agents. As a result, unexpected toxicities often become more evident in post-registry databases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite the critical need to increase our mechanistic understanding of physiologic and pathophysiologic cellular mechanisms in order to design rational "targeted" anticancer therapy, the clinical correlates of basic science discoveries are in most cases too vague or unexplained to provide information about expected side effects and how to prevent them with rational drug design. In most cases, we simply do not know if cardiovascular toxicity results from a direct effect of the drug on the intended molecular target, or if it represents an "off-target" effect [
         <a href="#rid169">
          169
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To further complicate the development of generally applicable therapeutic approaches, evidence suggests that cardiovascular toxicity may not only occur during the course of treatment and worsen with higher cumulative doses, but it may resolve despite continued treatment, or may develop years after therapy is completed in some patients. We are also just beginning to understand how genetic predisposition may affect an individual's risk and clinical pattern of cardiovascular toxicity. Additional fundamental, clinical, and epidemiologic research is required to resolve these questions around the use of each of the existing classes of anticancer drugs and those that will become available in the future.
        </p>
        <p>
        </p>
        <p>
         Despite these limitations, some general principles apply for minimizing the development of cardiovascular toxicity across all classes of anticancer agents, including the molecularly targeted agents.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, the risk of cardiovascular toxicity and the need for treatment gradually increase if patients do not receive primary and secondary prevention measures  (
         <a class="graphic graphic_figure graphicRef99624" href="/z/d/graphic/99624.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid169">
          169
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Primary prevention to reduce cardiovascular risk may be achieved by measures "that rest on common sense" [
         <a href="#rid102">
          102
         </a>
         ]. Management of pre-existing comorbidities (hypertension, systolic or diastolic cardiac dysfunction, arrhythmias, metabolic disorders) should reasonably be optimized and a healthy lifestyle encouraged (cessation of smoking, weight reduction towards ideal, increased exercise) both before and after cancer therapy is begun.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is evidence that administration of certain cardiac agents (eg, beta-blockers and angiotensin converting enzyme [ACE] inhibitors) to patients without cardiac risk factors may be beneficial. As an example, ACE inhibitors have been shown to improve outcomes and slow disease progression in patients with left ventricular systolic dysfunction due to a variety of causes. However, the role of ACE inhibitors in the treatment of patients with chemotherapy-induced cardiotoxicity is less clear. (See
         <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity", section on 'Management of systolic dysfunction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A separate question relates to the potential protective effect of ACE inhibitors for preventing the development of left ventricular dysfunction in response to chemotherapy in patients who are at risk. Patients with elevations in serum cardiac troponin levels in response to chemotherapy may be at an increased risk for developing impaired left ventricular dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The potential protective effect of ACE inhibitors in patients with elevated serum cardiac troponin following chemotherapy was evaluated in a randomized trial; the high-dose chemotherapy regimen included a variety of anthracycline-containing and non-anthracycline-containing agents [
         <a href="#rid170">
          170
         </a>
         ]. From a total population of 473 cancer patients, 114 with an elevated troponin T were randomly assigned to one year of treatment with the ACE inhibitor
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         (2.5 mg daily, titrated to a maximum of 20 mg daily), or to no enalapril. After one year, patients assigned to no treatment had a significant reduction in left ventricular ejection fraction (LVEF), while those in the ACE inhibitor group did not (LVEF at 12 months 48 versus 62 percent). In addition, the primary endpoint, an absolute reduction in LVEF of 10 percent or more, was reached in 43 percent of the untreated patients, but in none of the patients treated with enalapril.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Secondary prevention measures such as the use of ACE inhibitors require that patients be monitored during and after cancer therapy and managed when toxicity signals appear. Potentially useful biomarkers for cardiotoxicity include elevation in cardiac markers (brain natriuretic peptide [BNP] or troponin) and the development of systolic or diastolic dysfunction on tests such as echocardiography. Unfortunately, there are no universally applicable imaging modalities or markers to reliably predict the risk of developing post-treatment cardiovascular toxicity, and routine serial testing with these modalities cannot be recommended for all patients in the absence of clinical indications. (See
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity", section on 'Preventive management of anthracycline therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1443964929">
         <span class="h1">
          MONITORING DURING AND AFTER THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to anthracyclines and HER2-targeted treatments, there are few guidelines as to optimal monitoring for cardiovascular disease in patients receiving any of the potentially cardiotoxic agents discussed above [
         <a href="#rid171">
          171-174
         </a>
         ]. In the absence of specific guidelines for cardiac monitoring for a potentially cardiotoxic agent, evaluation and monitoring of left ventricular ejection fraction (LVEF) or other biomarkers should be considered on a case-by-case basis. The toxicity profile, patient, and disease characteristics should be considered when making this decision. Typically, LVEF monitoring parameters recommended in the United States Prescribing Information for individual agents should be followed. Patients with underlying cardiovascular disease and those developing cardiovascular signs or symptoms during treatment may need more frequent follow-up testing, although guidelines have not specifically addressed this point.
        </p>
        <p>
         An important point is that when treatment is palliative but potentially life prolonging, the benefits of therapy often outweigh the risks of LV dysfunction. In this situation, many clinicians evaluate for LV dysfunction only upon the development of symptoms. Conversely, when the goal of therapy is cure or long-term remission, a more aggressive schedule of monitoring for LV dysfunction may be advisable.
        </p>
        <p>
         When starting an agent that may cause or worsen hypertension, serial blood pressure monitoring should be performed and maintained while on the particular drug. Proposed guidelines regarding intervention for treatment-related hypertension are provided in the table  (
         <a class="graphic graphic_table graphicRef73373" href="/z/d/graphic/73373.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
         Monitoring may also be important for cancer survivors. Survivors tend to develop more comorbidities and reduce their overall levels of physical activity, which may cause subclinical cardiovascular toxicity to become manifest later in life (concept of "multiple hit hypothesis" for risk of cardiovascular disease [
         <a href="#rid175">
          175
         </a>
         ]). Hence, it is not surprising that outcomes may be better when cancer survivors who have been treated with potentially cardiotoxic drugs are referred to centers with expertise in long-term surveillance and risk-based medical care [
         <a href="#rid176">
          176
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/17017.html" rel="external">
          "Cancer survivorship: Cardiovascular and respiratory issues"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17024.html" rel="external">
          "Treatment of alcohol use and smoking for cancer survivors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H54">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy and cardiovascular complications
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cancer patients receiving chemotherapy have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of cardiovascular disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anthracycline and anthracycline-like agents, agents that target the human epidermal growth factor receptor 2 (HER2), such as
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , and fluoropyrimidines are the most frequent anticancer agents associated with cardiac toxicity. Cardiotoxicity associated with these agents is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/774.html" rel="external">
          "Cardiotoxicity of trastuzumab and other HER2-targeted agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89348.html" rel="external">
          "Fluoropyrimidine-associated cardiotoxicity: Incidence, clinical manifestations, mechanisms, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         However, many other agents, including conventional cytotoxic and molecularly targeted agents, have the potential to cause cardiotoxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific risks
         </strong>
         – Among the serious complications that have been reported with agents other than anthracyclines, HER2-targeted therapies, and fluoropyrimidines are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Arrhythmias (eg, histone deacetylase inhibitors,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         .
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">
          vandetanib
         </a>
         ,
         <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">
          crizotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         , taxanes).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myocardial necrosis causing a dilated cardiomyopathy and clinical heart failure (eg,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         and other multitargeted tyrosine kinase inhibitors [TKIs] that target the vascular endothelial growth factor [VEGF],
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         , taxanes [in combination with anthracyclines]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prolongation of the correct QT (QTc) interval, which can occur with many agents, including
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">
          arsenic trioxide
         </a>
         ,
         <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">
          crizotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">
          osimertinib
         </a>
         and
         <a class="drug drug_general" data-topicid="132715" href="/z/d/drug information/132715.html" rel="external">
          mobocertinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          selpercatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">
          vandetanib
         </a>
         ,
         <em>
          BRAF
         </em>
         inhibitors, histone deacetylase inhibitors, and TKIs that target BCR::ABL1.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pericarditis (eg,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pericardial effusions (eg,
         <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">
          all-trans retinoic acid
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Heart failure, myocardial ischemia, and cardiac arrest (proteasome inhibitors, antiangiogenic therapies,
         <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">
          osimertinib
         </a>
         and
         <a class="drug drug_general" data-topicid="132715" href="/z/d/drug information/132715.html" rel="external">
          mobocertinib
         </a>
         , interferon, interleukin-2 [IL-2], and
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Arterial occlusive events (eg,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         ). (See
         <a class="local">
          'Agents targeting BCR::ABL1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fluid retention, which may be manifest as a pericardial or pleural effusion (
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , IL-2).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention and monitoring
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For all patients receiving potentially cardiotoxic therapies, primary prevention to reduce cardiovascular risk should be emphasized. Management of preexisting hypertension, systolic or diastolic cardiac dysfunction, arrhythmias, and metabolic/electrolyte disorders should be optimized and a healthy lifestyle encouraged (cessation of smoking, weight reduction towards ideal, increased exercise) prior to and during therapy. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When starting an agent that may cause or worsen hypertension (eg, antiangiogenic agents), serial blood pressure monitoring should be performed during therapy. Proposed guidelines for treatment-related hypertension are provided  (
         <a class="graphic graphic_table graphicRef73373" href="/z/d/graphic/73373.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In contrast to anthracyclines, there are no specific guidelines for cardiac monitoring during therapy with a potentially cardiotoxic agent. Evaluation and monitoring of left ventricular ejection fraction (LVEF) or other biomarkers should be considered on a case-by-case basis, taking into account the toxicity profile, patient, and disease characteristics. (See
         <a class="local">
          'Monitoring during and after therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         LVEF monitoring parameters recommended in the United States Prescribing Information for individual agents should be followed. Patients with underlying cardiovascular disease and those developing cardiovascular signs or symptoms during treatment may need more frequent follow-up testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When treatment is palliative but potentially life prolonging, and benefits of therapy outweigh the risks of LV dysfunction, LV dysfunction can be evaluated only upon the development of symptoms. When the goal of therapy is cure or long-term remission, a more aggressive schedule of monitoring for LV dysfunction may be advisable.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50:441.
          </a>
         </li>
         <li class="breakAll">
          Gutheil J, Finucane D. Antimetabolites. In: The Chemotherapy Sourcebook, 3rd ed, Perry MC (Ed), Lippincott, Williams and Wilkins, Philadelphia 2001. p.208.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Besien K, Devine S, Wickrema A, et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003; 32:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grem JL, King SA, Chun HG, Grever MR. Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy. Am J Hematol 1991; 38:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koczwara B, Spangenthal E, Bernstein SH. The development of congestive cardiac failure in a patient with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 1997; 26:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasser AB, Tièche M, Brunner KW. Neurologic and cardiac toxicity following iv application of methotrexate. Cancer Treat Rep 1982; 66:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kettunen R, Huikuri HV, Oikarinen A, Takkunen JT. Methotrexate-linked ventricular arrhythmias. Acta Derm Venereol 1995; 75:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 2005; 25:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 1995; 19:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997; 75:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med 1984; 144:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep 1986; 70:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris AL, Wong C. Myocardial ischaemia, radiotherapy, and vinblastine. Lancet 1981; 1:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantor AF, Greene MH, Boice JD, et al. Are vinca alkaloids associated with myocardial infarction? Lancet 1981; 1:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975; 36:1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somers G, Abramov M, Witter M, Naets JP. Letter: Myocardial infarction: a complication of vincristine treatment? Lancet 1976; 2:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yancey RS, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep 1982; 66:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zabernigg A, Gattringer C. Myocardial infarction associated with vinorelbine (Navelbine). Eur J Cancer 1996; 32A:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cargill RI, Boyter AC, Lipworth BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Respir Med 1994; 88:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993; :117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9:1704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13:2688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lluch A, Ojeda B, Colomer R, et al. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer 2000; 89:2169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahman Z, Champlin R, Rondon G, et al. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 1997; 24:S17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano SH, Booser DJ, Murray JL, et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002; 8:3360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer 2003; 97:40.
          </a>
         </li>
         <li class="breakAll">
          FDA approves ABRAXANE(TM) for metastatic breast cancer. Available at: https://www.eurekalert.org/pub_releases/2005-01/hp-faa010705.php.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993; 53:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12:2301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves A, Viret F, Ciccolini J, et al. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clin Cancer Res 2003; 9:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra V, Dorr VJ, Lyss AP, et al. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer 2004; 5:377.
          </a>
         </li>
         <li class="breakAll">
          Eribulin mesylate injection. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf (Accessed on November 22, 2010).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavin RE, Millan JC, Mullins GM. Pathology of high dose intermittent cyclophosphamide therapy. Hum Pathol 1975; 6:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appelbaum F, Strauchen JA, Graw RG Jr, et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtman SM, Ratain MJ, Van Echo DA, et al. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst 1993; 85:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanda Y, Matsumura T, Maki K, et al. Fatal cardiac toxicity in two patients receiving same-day administration of cyclophosphamide and cytarabine as conditioning for hematopoietic stem cell transplantation. Haematologica 2001; 86:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishida S, Doki N, Shingai N, et al. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ann Hematol 2016; 95:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qazilbash MH, Amjad AI, Qureshi S, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 2009; 15:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh J, Whited L, Saliba RM, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv 2021; 5:5599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989; 24:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bramwell V, Quirt I, Warr D, et al. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 1989; 81:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 1990; 17:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomirotti M, Riundi R, Pulici S, et al. Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP). Tumori 1984; 70:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortimer JE, Crowley J, Eyre H, et al. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study. Cancer 1992; 69:1220.
          </a>
         </li>
         <li class="breakAll">
          Perry MC. Effects of chemotherapy on the heart. In: Cancer and the Heart, Kapoor AS (Ed), Springer Verlag, New York 1986. p.223.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 2012; 48:2361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 2016; 34:786.
          </a>
         </li>
         <li class="breakAll">
          Trabectedin for injection. United States Prescribing Information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=472bd78e-be17-4b9d-90f4-9482c3aec9ff (Accessed on November 04, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 1997; 76:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij J, van Zanten T, Souren T, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 1987; 60:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij J, Funke-Küpper AJ, Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 1988; 5:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzdar AU, Legha SS, Tashima CK, et al. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep 1978; 62:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij J, van der Burg ME, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravry MJ. Cardiotoxicity of mitomycin C in man and animals. Cancer Treat Rep 1979; 63:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durkin WJ, Pugh RP, Solomon J, et al. Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology 1976; 33:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer 1987; 59:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           House KW, Simon SR, Pugh RP. Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease. Clin Cardiol 1992; 15:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards GS, Lane M, Smith FE. Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: possible association with severe coronary artery disease. Cancer Treat Rep 1979; 63:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelzang NJ, Frenning DH, Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 1980; 64:1159.
          </a>
         </li>
         <li class="breakAll">
          Rasool HJ. Antibodies. In: The Chemotherapy Sourcebook, 3rd ed, Perry MC (Ed), Lippincott, Williams and Wilkins, Philadelphia 2001. p.394.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm 2003; 60:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millward PM, Bandarenko N, Chang PP, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005; 45:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004; 104:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991; 12:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schecter JP, Jones SE, Jackson RA. Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both. Cancer Chemother Rep 1975; 59:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yano S, Shimada K. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J 1996; 60:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino S, Ratanatharathorn V, Karanes C, et al. Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon. J Cancer Res Clin Oncol 1987; 113:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friess GG, Brown TD, Wrenn RC. Cardiovascular rhythm effects of gamma recombinant DNA interferon. Invest New Drugs 1989; 7:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budd GT, Bukowski RM, Miketo L, et al. Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy. Cancer Chemother Pharmacol 1984; 12:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunberg SM, Kempf RA, Itri LM, et al. Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 1985; 69:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. BMJ 1990; 300:1174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deyton LR, Walker RE, Kovacs JA, et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989; 321:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmerman S, Adkins D, Graham M, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother 1994; 9:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989; 7:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crum E. Biological-response modifier--induced emergencies. Semin Oncol 1989; 16:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White RL Jr, Schwartzentruber DJ, Guleria A, et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74:3212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muluneh B, Richardson DR, Hicks C, et al. Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach. J Clin Oncol 2019; 37:2719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc 2017; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol 2017; 35:2490.
          </a>
         </li>
         <li class="breakAll">
          Brigatinib tablets. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf?et_cid=39193335&amp;et_rid=907466112&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2017%2f208772lbl.pdf (Accessed on June 01, 2017).
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf (Accessed on October 13, 2023).
         </li>
         <li class="breakAll">
          Drug label information for MEKINIST-trametinib tablet and powder. DailyMed. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1 (Accessed on October 13, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107.
          </a>
         </li>
         <li class="breakAll">
          Mekinist (trametinib) tablets, for oral use. US FDA approved product information; Research Triangle Park, NC: GlaxoSmithKline; May 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl.pdf (Accessed on August 13, 2013).
         </li>
         <li class="breakAll">
          Crizotinib capsules. United States Prescribing Information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7 (Accessed on September 10, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ou SH, Tong WP, Azada M, et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 2013; 119:1969.
          </a>
         </li>
         <li class="breakAll">
          Ceritinib capsules. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf?et_cid=33681002&amp;et_rid=585254827&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2014%2f205755lbl.pdf (Accessed on April 29, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol 2019; 74:1667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 2019; 134:1919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Qadir H, Sabrie N, Leong D, et al. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. J Clin Oncol 2021; 39:3453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien S, Hillmen P, Coutre S, et al. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18:648.
          </a>
         </li>
         <li class="breakAll">
          TUKYSA® (tucatinib) tablets, for oral use. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf (Accessed on January 20, 2023).
         </li>
         <li class="breakAll">
          US Prescribing information for acalabrutinib available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd4835ef-e1bc-4997-a399-1ffa2556fbfe (Accessed on April 14, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhat SA, Gambril J, Azali L, et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood 2022; 140:2142.
          </a>
         </li>
         <li class="breakAll">
          JAYPIRCATM (pirtobrutinib) tablets, for oral use. US Food and Drug Administration. Available at: https://pi.lilly.com/us/jaypirca-uspi.pdf (Accessed on January 31, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández A, Sanguino A, Peng Z, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007; 117:4044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010; 116:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estabragh ZR, Knight K, Watmough SJ, et al. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 2011; 35:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perik PJ, Rikhof B, de Jong FA, et al. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008; 19:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/ https://www.nccn.org/professionals/physician_gls/ (Accessed on November 29, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25:3362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu Rmilah AA, Lin G, Begna KH, et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer 2020; 147:3160.
          </a>
         </li>
         <li class="breakAll">
          Dasatinib tablets. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf (Accessed on June 09, 2020).
         </li>
         <li class="breakAll">
          Bosutinib tablets. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf?et_cid=29953027&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203341lbl.pdf (Accessed on September 05, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 2021; 138:2042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casavecchia G, Galderisi M, Novo G, et al. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Fail Rev 2020; 25:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caocci G, Mulas O, Abruzzese E, et al. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol 2019; 37:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J 2016; 37:2315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AP, Glennon MS, Umbarkar P, et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res 2019; 115:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latifi Y, Moccetti F, Wu M, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood 2019; 133:1597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res 2016; 48:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int J Cardiol 2020; 316:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santoro M, Accurso V, Mancuso S, et al. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors. Chemotherapy 2019; 64:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breccia M, Pregno P, Spallarossa P, et al. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Ann Hematol 2017; 96:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saussele S, Haverkamp W, Lang F, et al. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematol 2020; 143:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molica M, Scalzulli E, Colafigli G, et al. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol 2019; 10:2040620719826444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30:1648.
          </a>
         </li>
         <li class="breakAll">
          US prescribing infomation for asciminib available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf (Accessed on November 09, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020; 382:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac Safety of Osimertinib: A Review of Data. J Clin Oncol 2021; 39:328.
          </a>
         </li>
         <li class="breakAll">
          EXKIVITY (mobocertinib) capsules, for oral use. United States Prescribing Information. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf (Accessed on September 22, 2023).
         </li>
         <li class="breakAll">
          Quizartinib tablets, for oral use. US Food and Drug Administration (FDA) approved product information. Revised July 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216993s000lbl.pdf (Accessed on July 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Mehren M, Serrano C, Bauer S, et al. INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). Ann Oncol 2019; 30S: ESMO #LBA87.
          </a>
         </li>
         <li class="breakAll">
          Ripretinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf (Accessed on May 19, 2020).
         </li>
         <li class="breakAll">
          Selpercatinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf (Accessed on May 12, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson DR, Parish PC, Tan X, et al. Association of QTc Formula With the Clinical Management of Patients With Cancer. JAMA Oncol 2022; 8:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 2002; 7:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grote TH, Pineda LF, Figlin RA, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am 1997; 3:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996; 28:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boike SC, Ilson B, Zariffa N, Jorkasky DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997; 54:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunt TL, Cramer M, Shah A, et al. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995; 35:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jantunen IT, Kataja VV, Muhonen TT, Parviainen T. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 1996; 37:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubenstein EB, Gralla RJ, Hainsworth JD, et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer 1997; 79:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain. Lancet 1992; 340:1107.
          </a>
         </li>
         <li class="breakAll">
          Carfilzomib for injection. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf?et_cid=29661884&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f202714lbl.pdf (Accessed on August 13, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120:2817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornell RF, Ky B, Weiss BM, et al. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol 2019; 37:1946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grandin EW, Ky B, Cornell RF, et al. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 2015; 21:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12:3762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006; 12:3997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvatorelli E, Menna P, Cantalupo E, et al. The concomitant management of cancer therapy and cardiac therapy. Biochim Biophys Acta 2015; 1848:2727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114:2474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. JCO Oncol Pract 2021; 17:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020; 22:1945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc 2020; 9:e018403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 2010; 334:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan PC, Ford JS, Henderson TO, et al. Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27:2363.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2812 Version 76.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8193429" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Fluorouracil cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8233284" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8233284" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12942092" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951329" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9322907" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The development of congestive cardiac failure in a patient with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7093971" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Neurologic and cardiac toxicity following iv application of methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8615061" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Methotrexate-linked ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16164401" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7869742" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9322684" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pericarditis induced by high-dose cytosine arabinoside chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6477012" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pericarditis induced by high-dose cytarabine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3708625" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Apparent myocardial ischemia associated with vinblastine administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6110992" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Myocardial ischaemia, radiotherapy, and vinblastine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6112479" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Are vinca alkaloids associated with myocardial infarction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1243105" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Vincristine-induced myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/60549" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Letter: Myocardial infarction: a complication of vincristine treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7060049" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Vindesine-associated angina and ECG changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8911131" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Myocardial infarction associated with vinorelbine (Navelbine)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7809448" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Reversible myocardial ischaemia following vincristine containing chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7912518" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A reassessment of cardiac toxicity associated with Taxol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1678781" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cardiac disturbances during the administration of taxol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7595726" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8905026" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11147586" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9374100" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12429622" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12491503" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12491503" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8093854" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7911160" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7964944" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12538457" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15585077" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15585077" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17968020" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17606974" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7235784" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cardiotoxicity associated with high-dose cyclophosphamide therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1183993" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pathology of high dose intermittent cyclophosphamide therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/54581" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2045862" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8340944" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11532636" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Fatal cardiac toxicity in two patients receiving same-day administration of cyclophosphamide and cytarabine as conditioning for hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27079957" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19747634" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34592759" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8416155" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2791194" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Ifosfamide cardiotoxicity in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315425" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2778839" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2504890" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2110385" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6588670" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310889" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310889" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22541893" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26371143" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26371143" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9535170" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3109726" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3137399" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/688243" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Adriamycin and mitomycin C: possible synergistic cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3101142" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/445510" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cardiotoxicity of mitomycin C in man and animals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/64951" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Treatment of advanced lymphomas with bleomycin (NSC-125066).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2435402" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Acute chest pain syndrome during bleomycin infusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1371094" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/87274" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: possible association with severe coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6161700" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Coronary artery disease after treatment with bleomycin and vinblastine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6161700" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Coronary artery disease after treatment with bleomycin and vinblastine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12951753" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Monoclonal antibodies in the treatment of cancer, Part 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16131381" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15073032" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1713559" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1203893" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8741246" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1704826" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Cardiotoxicity of interferon. A review of 44 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3597523" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2507475" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Cardiovascular rhythm effects of gamma recombinant DNA interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6690072" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4028036" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3177405" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Recombinant alpha 2 interferon-related cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2346805" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Reversible cardiomyopathy induced by interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2638573" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7719376" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2783338" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cardiorespiratory effects of immunotherapy with interleukin-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2647914" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2688117" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Biological-response modifier--induced emergencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7982185" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31310577" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29217664" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23841729" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475456" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475456" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475456" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475456" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23248257" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22663011" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Improved survival with MEK inhibition in BRAF-mutated melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22663011" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Improved survival with MEK inhibition in BRAF-mutated melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22663011" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Improved survival with MEK inhibition in BRAF-mutated melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23505007" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23505007" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31558250" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Cardiovascular Toxicities Associated With Ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31582362" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Hypertension and incident cardiovascular events following ibrutinib initiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34464154" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30061088" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30061088" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30061088" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35917449" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Ventricular arrhythmias and sudden death events following acalabrutinib initiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35917449" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Ventricular arrhythmias and sudden death events following acalabrutinib initiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16862153" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18060038" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449798" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Congestive heart failure is a rare event in patients receiving imatinib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17336514" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19303137" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19885836" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21030079" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17962203" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19248973" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17664484" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Molecularly targeted oncology therapeutics and prolongation of the QT interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32449208" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32449208" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32449208" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24180494" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29567798" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34407543" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32026180" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30892724" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27222591" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention&amp;Rehabilitation (EACPR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30629146" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30692122" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27505637" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32470534" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31825920" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27686083" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31590170" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30854182" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27121688" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27121688" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27959700" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31751012" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33356419" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Cardiac Safety of Osimertinib: A Review of Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33356419" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Cardiac Safety of Osimertinib: A Review of Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33356419" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Cardiac Safety of Osimertinib: A Review of Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36136321" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Association of QTc Formula With the Clinical Management of Patients With Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854548" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9072308" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8797136" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9161624" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7560251" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8599877" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Effects of granisetron with doxorubicin or epirubicin on ECG intervals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9070501" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1357506" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Ondansetron and chest pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1357506" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Ondansetron and chest pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22833546" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31188726" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15958804" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16206291" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25433360" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16778104" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16818698" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577020" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19826124" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Histone deacetylase inhibitors in cancer therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25596534" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : The concomitant management of cancer therapy and cardiac therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17101852" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33689453" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32463967" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31959335" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32893704" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20335321" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Pharmacological foundations of cardio-oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255308" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
